Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Lithium Markt ist zurück - und Simon Clarke ist mit dabei!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
10.10.25 | 21:25
21,400 Euro
+0,94 % +0,200
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
20,85021,35012.10.
20,95021,40010.10.

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.10.Jefferies raises Nanobiotix stock price target to EUR21.00 on broad cancer potential5
06.10.Nanobiotix: Jefferies erhöht Kursziel auf 21,00 EUR wegen breiten Krebstherapie-Potenzials8
NANOBIOTIX Aktie jetzt für 0€ handeln
02.10.Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug5
02.10.Nanobiotix stock jumps on positive esophageal cancer treatment data2
02.10.Positive Studiendaten zu Speiseröhrenkrebs-Therapie beflügeln Nanobiotix-Aktie3
01.10.Nanobiotix S.A.: NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer149Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective...
► Artikel lesen
01.10.Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M2
01.10.Leerink Partners raises Nanobiotix stock price target to $24 on pipeline progress2
30.09.Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results655PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches...
► Artikel lesen
30.09.Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer8
30.09.Nanobiotix stock soars after promising cancer treatment results3
30.09.Nanobiotix S.A.: NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC206Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and...
► Artikel lesen
30.09.Nanobiotix S.A. - 6-K, Report of foreign issuer-
18.09.Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday7
18.09.Nanobiotix soars on positive phase 1 results for JNJ-1900 in melanoma23
17.09.Nanobiotix S.A.: NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant ...468Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase...
► Artikel lesen
12.09.Nanobiotix S.A. - 6-K, Report of foreign issuer2
12.09.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
27.08.Nanobiotix S.A. - 6-K, Report of foreign issuer3
27.08.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1